Teladoc, a leading telehealth provider, is partnering with a manufacturer of continuous glucose monitoring (CGM) systems, DexCom, to offer CGM-powered insights to its members with Type 2 diabetes. The program will combine data from DexCom’s wearable device and lifestyle data from Teladoc to give members a contextual understanding of how lifestyle decisions could impact glucose levels.  

The pilot CGM-powered insights program will be launched to select members of Livongo, a subsidiary of Teladoc, who will receive an integrated product consisting of DexCom CGM technology and CGM powered insights at no cost. Teladoc and DexCom plan to broaden the pilot program’s reach throughout 2021. 

Founded in 2002, Teladoc Health is a well-established player in the US telehealth market, offering a range of virtual care services. Subsidiary Livongo offers preventive healthcare solutions by aggregating data from remote monitoring devices to manage chronic conditions. In October 2020, Teladoc Health completed its merger with Livongo in a deal valued at USD 18.5 billion. The pilot program comes on the back of a strategic relationship that was formed between Livongo and Dexcom in January 2020.